MediFind

Find a Doctor

Robert J. Motzer

Memorial Solid Tumor Group
Oncology, Internal Medicine
Male
Practicing approx. 39 years

Bio


Robert Motzer is an Oncologist and an Internal Medicine specialist in New York, New York. He has been an author on 364 peer reviewed articles in the past 15 years. Dr. Motzer's top three areas of expertise are Chromophobe Renal Cell Carcinoma, Renal Cell Carcinoma, and Testicular Cancer. He is licensed to treat patients in NY.

Contact

1275 York Ave
New York, NY 10065, US

Latest Research


Latest Advance
Study
  • Condition: Advanced Solid Tumors
  • Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • Treatment Used: Lenvatinib Plus Pembrolizumab
  • Number of Patients: 137
  • Published —
The study researched the outcomes of lenvatinib plus pembrolizumab in patients with advanced kidney cancer, endometrial cancer, and other advanced solid tumors.
Latest Advance
Study
  • Condition: Advanced Renal Cell Carcinoma
  • Journal: European journal of cancer (Oxford, England : 1990)
  • Treatment Used: Cabozantinib Versus Everolimus
  • Number of Patients: 658
  • Published —
In this study, researchers compared the effectiveness of cabozantinib versus everolimus for the treatment of advanced renal cell carcinoma.
Latest Advance
Study
  • Condition: Advanced Renal Cell Carcinoma
  • Journal: Cancer science
  • Treatment Used: Avelumab plus Axitinib vs Sunitinib
  • Number of Patients: 67
  • Published —
In this study, researchers compared the effectiveness of avelumab plus axitinib vs sunitinib for the treatment of advanced kidney cancer in Japanese patients.
Latest Advance
Study
  • Condition: Advanced renal cell carcinoma
  • Journal: European urology
  • Treatment Used: Nivolumab plus ipilimumab
  • Number of Patients: 1051
  • Published —
The study researched the use of Nivolumab plus ipilimumab for patients with advanced renal cell carcinoma.
Latest Advance
Study
  • Condition: Advanced renal cell carcinoma
  • Journal: The Lancet. Oncology
  • Treatment Used: Nivolumab plus ipilimumab versus sunitinib
  • Number of Patients: 1096
  • Published —
The study compared nivolumab plus ipilimumab versus sunitinib (chemotherapies) for advanced renal cell carcinoma.
Latest Advance
Study
  • Condition: Advanced Renal Cell Carcinoma (aRCC)
  • Journal: Clinical genitourinary cancer
  • Treatment Used: Nivolumab vs. Everolimus
  • Number of Patients: 0
  • Published —
This study compared quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) between nivolumab and everolimus among previously treated patients with advanced renal cell carcinoma (aRCC).
Latest Advance
Study
  • Condition: Metastatic Renal cell Carcinoma
  • Journal: Lancet (London, England)
  • Treatment Used: Atezolizumab plus bevacizumab versus sunitinib
  • Number of Patients: 915
  • Published —
The objective of the study was to determine the effects of Atezolizumab plus bevacizumab versus sunitinib on Metastatic Renal cell Carcinoma.
Latest Advance
Study
  • Condition: Metastatic Chromophobe Renal Cell Carcinoma (ChRCC)
  • Journal: Clinical genitourinary cancer
  • Treatment Used: Nephrectomy
  • Number of Patients: 109
  • Published —
This study evaluated clinical outcomes and genomic features in metastatic chromophobe renal cell cancer (ChRCC) with sarcomatoid features (SF).
Latest Advance
Study
  • Condition: Renal-cell carcinoma
  • Journal: The New England journal of medicine
  • Treatment Used: Avelumab plus axitinib versus sunitinib
  • Number of Patients: 886
  • Published —
This study compared avelumab plus axitinib versus sunitinib for patients with advanced renal-cell carcinoma.
Latest Advance
Study
  • Condition: Advanced Renal Cell Carcinoma
  • Journal: The Lancet. Oncology
  • Treatment Used: Nivolumab plus Ipilimumab vs. Sunitinib
  • Number of Patients: 847
  • Published —
This trial aimed to assess the health related quality of life with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.
Latest Advance
Study
  • Condition: Clear Cell Renal Cell Cancer (ccRCC)
  • Journal: Cancer discovery
  • Treatment Used: Tyrosine kinase inhibitors (TKI)
  • Number of Patients: 0
  • Published —
This study reported an integrated genomic and transcriptomic analysis of patients with metastatic clear cell renal cell carcinoma (ccRCC) treated with tyrosine kinase inhibitors (TKI) therapy and identify predictors of response.
Latest Advance
Study
  • Condition: High-Risk Renal Cell Carcinoma
  • Journal: Annals of oncology : official journal of the European Society for Medical Oncology
  • Treatment Used: Adjuvant Sunitinib
  • Number of Patients: 0
  • Published —
This study tested the safety and efficacy of using an adjuvant sunitinib to treat patients with high-risk renal cell carcinoma.
Latest Advance
Study
  • Condition: High-Risk Renal Cell Carcinoma
  • Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
  • Treatment Used: Sunitinib
  • Number of Patients: 142
  • Published —
This analysis evaluated sunitinib versus placebo in patients with high-risk renal cell carcinoma.
Latest Advance
Study
  • Condition: Renal cell carcinoma
  • Journal: British journal of cancer
  • Treatment Used: Cabozantinib versus Everolimus
  • Number of Patients: 470
  • Published —
The study aimed to determine the effects of using Cabozantinib versus Everolimus to treat renal cell carcinoma.
Latest Advance
Study
  • Condition: Renal Cell Carcinoma
  • Journal: Expert review of anticancer therapy
  • Treatment Used: Tivozanib
  • Number of Patients: 0
  • Published —
This study compared tivozanib vs. sorafenib for the treatment of VEGF- (Vascular endothelial growth factor) and mTOR therapy-naïve advanced renal cell cancer (RCC).
Latest Advance
Study
  • Condition: Advanced Refractory Renal Cell Carcinomas (mRCCs)
  • Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
  • Treatment Used: Anti-ENPP3 Antibody-Drug Conjugates
  • Number of Patients: 60
  • Published —
This study determined the safety, pharmacokinetics, and recommended phase II dose of an antibody-drug conjugate (ADC) targeting ectonucleotide phosphodiesterases-pyrophosphatase 3 (ENPP3) conjugated to monomethyl auristatin F (MMAF) in subjects with advanced metastatic renal cell carcinoma (mRCC).
Latest Advance
Study
  • Condition: Metastatic non-clear cell renal cell carcinoma (ccRCC)
  • Journal: Cancer immunology research
  • Treatment Used: Programmed death 1 (PD-1) and PD ligand 1 (PD-L1) inhibitors
  • Number of Patients: 43
  • Published —
This study evaluated the efficacy of programmed death 1 (PD-1) and PD ligand 1 (PD-L1) inhibitors in patients with metastatic non-clear cell renal cell carcinoma (ccRCC) or sarcomatoid/rhabdoid differentiation.
Latest Advance
Study
  • Condition: Patients With Nonseminomatous Germ Cell Tumor (GCT)
  • Journal: Urology
  • Treatment Used: Liver Mass Resection With Retroperitoneal Lymph Node Dissection
  • Number of Patients: 36
  • Published —
This study evaluated the oncologic outcomes and histologic concordance of post-chemotherapy residual liver mass resection with post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND).
Latest Advance
Study
  • Condition: Advanced Renal Cell Carcinoma (RCC)
  • Journal: British journal of cancer
  • Treatment Used: Cabozantinib vs. Everolimus
  • Number of Patients: 658
  • Published —
This study compared cabozantinib (60?mg daily) or everolimus (10?mg daily) in patients with advanced renal cell cancer (RCC) who had received at least one prior VEGFR tyrosine kinase inhibitor.
Latest Advance
Study
  • Condition: Advanced Renal Cell Carcinoma (RCC)
  • Journal: European journal of cancer (Oxford, England : 1990)
  • Treatment Used: Tivozanib After Sorafenib
  • Number of Patients: 0
  • Published —
This study compared tivozanib with sorafenib in patients with advanced renal (kidney) cell carcinoma (RCC).

Clinical Trials


This doctor has not participated in any recent clinical trials.

All Publications
View All


Publication
Study
  • Journal: Journal of the National Comprehensive Cancer Network : JNCCN
  • Published —
NCCN Guidelines Insights: Kidney Cancer, Version 1.2021.
Publication
Study
  • Journal: Canadian Urological Association journal = Journal de l'Association des urologues du Canada
  • Published —
An evaluation of the role of tumor load in cytoreductive nephrectomy.

Contact

1275 York Ave
New York, NY 10065, US

Affiliations

  • Memorial Hospital For Cancer And Allied Diseases

Credentials

  • Graduate InstitutionUniversity Of Michigan Medical School
    1981
  • Licenses
    Internal Medicine in NY
  • Board Certifications
    Medical Oncology
    Internal Medicine

Insurance

Contact them to find out if they accept your insurance plan.